130 related articles for article (PubMed ID: 37184873)
1. Serum level of galectin-9 as a potential biomarker for high risk of malignancy in dermatomyositis.
Shih Y; Chen S; Huang J; Chen Y; Zhu Z; Zhao Q; Zhao X; Xue F; Xiang J; Chen X; Zhu X; Pan M; Wu J; Zheng J; Li H; Cao H
Rheumatology (Oxford); 2024 Jan; 63(1):251-258. PubMed ID: 37184873
[TBL] [Abstract][Full Text] [Related]
2. Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis.
Chen H; Peng Q; Yang H; Yin L; Shi J; Zhang Y; Wang G
J Rheumatol; 2018 Jun; 45(6):835-840. PubMed ID: 29419471
[TBL] [Abstract][Full Text] [Related]
3. Identification of distinct cytokine/chemokine profiles in dermatomyositis with anti-transcriptional intermediary factor 1-γ antibody.
Zhao Q; Chen Y; Diao L; Zhang S; Wu D; Xue F; Xia Q; Li H; Zheng J; Cao H
Rheumatology (Oxford); 2022 May; 61(5):2176-2184. PubMed ID: 34508564
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
[TBL] [Abstract][Full Text] [Related]
5. Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.
Li X; Huang Y; Liu Y; Yan S; Li L; Cheng L; Li H; Zhan H; Zhang F; Li Y
Clin Rheumatol; 2023 Mar; 42(3):817-830. PubMed ID: 36357631
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
[TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies.
Ly NTM; Ma N; Ueda-Hayakawa I; Nguyen CTH; Anada R; Okamoto H; Fujimoto M
J Dermatol Sci; 2021 Dec; 104(3):177-184. PubMed ID: 34772582
[TBL] [Abstract][Full Text] [Related]
8. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
10. Anti-transcriptional intermediary factor 1 gamma antibodies in cancer-associated myositis: a longitudinal study.
Dani L; Holmqvist M; Martínez MA; Trallero-Araguas E; Dastmalchi M; Svensson J; Labrador-Horrillo M; Selva-O'Callaghan A; Lundberg IE
Clin Exp Rheumatol; 2020; 38(1):67-73. PubMed ID: 31365334
[TBL] [Abstract][Full Text] [Related]
11. Anti-transcriptional intermediary factor 1-γ antibody as a biomarker in patients with dermatomyositis.
Shimizu K; Kobayashi T; Kano M; Hamaguchi Y; Takehara K; Matsushita T
J Dermatol; 2020 Jan; 47(1):64-68. PubMed ID: 31638280
[TBL] [Abstract][Full Text] [Related]
12. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis.
Wienke J; Pachman LM; Morgan GA; Yeo JG; Amoruso MC; Hans V; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Gelderman KA; Arkachaisri T; van Wijk F; van Royen-Kerkhof A
Arthritis Rheumatol; 2020 Jul; 72(7):1214-1226. PubMed ID: 32103637
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.
Wienke J; Bellutti Enders F; Lim J; Mertens JS; van den Hoogen LL; Wijngaarde CA; Yeo JG; Meyer A; Otten HG; Fritsch-Stork RDE; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Tekstra J; Hoogendijk JE; Deakin CT; de Jager W; van Roon JAG; van der Pol WL; Nistala K; Pilkington C; de Visser M; Arkachaisri T; Radstake TRDJ; van der Kooi AJ; Nierkens S; Wedderburn LR; van Royen-Kerkhof A; van Wijk F
Arthritis Rheumatol; 2019 Aug; 71(8):1377-1390. PubMed ID: 30861625
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
Fiorentino DF; Mecoli CA; Rosen MC; Chung LS; Christopher-Stine L; Rosen A; Casciola-Rosen L
J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040440
[TBL] [Abstract][Full Text] [Related]
15. Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population.
Dong R; Sun Y; Xu W; Xiang W; Li M; Yang Q; Zhu L; Ma Z
Front Immunol; 2023; 14():1197458. PubMed ID: 37539050
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis: a monocentric cross-sectional study.
Yang H; Yan T; Zhang X; Sun W; Liu L; Du Y; Xue J
Clin Rheumatol; 2022 Aug; 41(8):2439-2448. PubMed ID: 35422109
[TBL] [Abstract][Full Text] [Related]
17. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
[TBL] [Abstract][Full Text] [Related]
18. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis.
Oldroyd A; Sergeant JC; New P; McHugh NJ; Betteridge Z; Lamb JA; Ollier WE; Cooper RG; Chinoy H;
Rheumatology (Oxford); 2019 Apr; 58(4):650-655. PubMed ID: 30535395
[TBL] [Abstract][Full Text] [Related]
19. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
20. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
